MRC Technology highlights presentation of data for antibody candidate lambrolizumab developed using its humanization technology

The humanized antibody is now being developed by MSD, known as Merck in the US and Canada. Lambrolizumab is an investigational antibody therapy targeting Programmed Death receptor (PD-1) that is currently being evaluated for the treatment of patients with advanced melanoma, and other tumor types. MSD recently announced lambrolizumab has been designated as a Breakthrough Therapy for the treatment of patients with advanced melanoma by the U.S. Food and Drug Administration (FDA).

MRC Technology supports the ENTENTE Professional Exchange Program to strengthen European knowledge transfer

The primary focus of the exchange program is to strengthen knowledge transfer offices in universities, public research organisations, and hospitals, and to promote trans-national collaboration between industry and academia in the health sector. MRC Technology will provide participating Technology Transfer Officers with a clearer understanding of processes and priorities, and a unique insight into the organisation’s business culture and approach.

MRC Technology and EMBLEM collaborate to streamline drug development

The initiative will focus on identification of novel druggable targets in the field of small molecules and antibodies, and collaborating to fast track those targets through drug discovery to create potent and selective novel therapeutics. It brings together EMBLEM’s experience in supporting academics in one of the world’s leading locations for scientific research, with MRC Technology’s dedicated expertise in translating novel biology targets into lead stage therapeutic assets.

Global Drug Development Alliance in Nature Biotechnology

MRC Technology's Director of Drug Discovery, Justin Bryans, is quoted in a Nature Biotechnology article about the…

MRC Technology and Chinese Academy of Sciences collaboration yields humanized anti-CD146 antibody

The on-going collaboration between MRC Technology and the Institute of Biophysics, Chinese Academy of Sciences (IBP CAS) aims to develop the antibody as a cancer therapeutic.

Science and Technology Committee report on the “valley of death”

MRC Technology's CEO, Dave Tapolczay, gave evidence to the UK House of Commons Science and Technology Committee…

MRC Technology and MS Society launch joint ‘Call for Targets’

The call aims to to fast-track the discovery and development of novel drugs to slow, stop or reverse progression in MS or treat MS symptoms. The call to academic researchers seeks to fund further validation of small molecule and antibody targets prior to initiating a full scale drug discovery project to produce ‘drug-like’ molecules or therapeutic antibodies that have the potential to become therapies.

MRC Technology and AICR partnership reports success for cancer research

The partnership enables AICR to take advantage of MRC Technology’s IP management, technology transfer, and drug discovery expertise, to help maximise the health benefits and revenue derived from AICR-funded research. MRC Technology reviewed and monitored 25 priority projects from AICR's portfolio, and negotiated revenue sharing agreements for three of these projects.

Global Drug Development Alliance in SciBX

MRC Technology's Director of Corporate Partnerships, Mike Johnson, is quoted in a SciBX article about the Global…